Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash from Operations for 6 consecutive years, with 7515973.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 40.6% to 7515973.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 27786464.0 through Dec 2025, down 45.11% year-over-year, with the annual reading at 27786464.0 for FY2025, 45.11% down from the prior year.
  • Cash from Operations for Q4 2025 was 7515973.0 at Inhibikase Therapeutics, up from 10592730.0 in the prior quarter.
  • The five-year high for Cash from Operations was 2020498.0 in Q3 2021, with the low at 10592730.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 4833386.4, with a median of 4301159.0 recorded in 2021.
  • The sharpest move saw Cash from Operations tumbled 145828.38% in 2021, then surged 35.25% in 2024.
  • Over 5 years, Cash from Operations stood at 4095817.0 in 2021, then grew by 13.17% to 3556374.0 in 2022, then increased by 3.2% to 3442431.0 in 2023, then crashed by 55.28% to 5345575.0 in 2024, then crashed by 40.6% to 7515973.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 7515973.0, 10592730.0, and 5574231.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.